InPractice Survey on the Treatment of Hypercholesterolemia

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00523796
First received: August 30, 2007
Last updated: February 15, 2011
Last verified: February 2011
  Purpose

This is a multi-centre survey of patients who are currently on lipid-lowering pharmacological treatment. Data collection for each patient will take place at one visit.


Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: InPractice Survey on the Treatment of Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 2500
Study Start Date: February 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

primary care

Criteria

Inclusion Criteria:

  • Subject must be 18 years of age or older of either sex.
  • Subject is on lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00523796

Locations
Vietnam
Research Site
Hanoi, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Pham Gia Khai, Prof Vietnamese Cardiovascular Association
Study Chair: Nguyen Manh Phan, Prof Vietnamese Cardiovascular Association
Study Director: Than Trong Son, MD AstraZeneca
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00523796     History of Changes
Other Study ID Numbers: NIS-CVN-CRE-2007/1, VN-NIS-0001
Study First Received: August 30, 2007
Last Updated: February 15, 2011
Health Authority: Vietnam: Ho Chi Minh City Health Service

Keywords provided by AstraZeneca:
dyslipidemia
in practice survey
Vietnam

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on April 23, 2014